AR068368A1 - Formas solidas de dosificacion de azitromicina de liberacion controlada - Google Patents

Formas solidas de dosificacion de azitromicina de liberacion controlada

Info

Publication number
AR068368A1
AR068368A1 ARP080103847A ARP080103847A AR068368A1 AR 068368 A1 AR068368 A1 AR 068368A1 AR P080103847 A ARP080103847 A AR P080103847A AR P080103847 A ARP080103847 A AR P080103847A AR 068368 A1 AR068368 A1 AR 068368A1
Authority
AR
Argentina
Prior art keywords
solid forms
azithromycin dosage
controlled liberation
azithromycin
pharmaceutical form
Prior art date
Application number
ARP080103847A
Other languages
English (en)
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of AR068368A1 publication Critical patent/AR068368A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma farmacéutica solida para administracion oral que comprende azitromicina en una cantidad interior a la dosis mencionada que causa efectos secundarios gastrointestinales, cuya forma farmacéutica es una forma farmacéutica de liberacion controlada.
ARP080103847A 2007-09-05 2008-09-04 Formas solidas de dosificacion de azitromicina de liberacion controlada AR068368A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96750407P 2007-09-05 2007-09-05
US12/002,417 US8124123B2 (en) 2007-09-05 2007-12-17 Controlled release azithromycin solid dosages forms

Publications (1)

Publication Number Publication Date
AR068368A1 true AR068368A1 (es) 2009-11-11

Family

ID=40407900

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103847A AR068368A1 (es) 2007-09-05 2008-09-04 Formas solidas de dosificacion de azitromicina de liberacion controlada

Country Status (12)

Country Link
US (2) US8124123B2 (es)
EP (2) EP2197420A4 (es)
JP (2) JP2010538062A (es)
KR (2) KR20100063088A (es)
CN (2) CN101861138A (es)
AR (1) AR068368A1 (es)
AU (2) AU2008295579A1 (es)
BR (1) BRPI0816268A2 (es)
CA (2) CA2697496A1 (es)
RU (2) RU2010109358A (es)
WO (2) WO2009032037A1 (es)
ZA (2) ZA201001649B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
CN109875970B (zh) * 2019-01-08 2021-08-06 石家庄四药有限公司 阿奇霉素固体制剂及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CN1096862C (zh) * 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
BRPI0413927B8 (pt) * 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
CA2591923A1 (en) 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
SG161256A1 (en) * 2005-04-08 2010-05-27 Abbott Lab Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
JP2009514963A (ja) * 2005-11-09 2009-04-09 ドウ ファーマシューティカル サイエンシーズ 肉芽腫性酒さの治療ためのアジスロマイシン
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne

Also Published As

Publication number Publication date
CN101861138A (zh) 2010-10-13
AU2008295579A1 (en) 2009-03-12
EP2197420A4 (en) 2010-10-20
US20090060994A1 (en) 2009-03-05
RU2010109358A (ru) 2011-10-20
WO2009032037A1 (en) 2009-03-12
RU2010109359A (ru) 2011-10-20
WO2009032268A1 (en) 2009-03-12
JP2010538066A (ja) 2010-12-09
ZA201001649B (en) 2010-11-24
EP2197420A1 (en) 2010-06-23
BRPI0816268A2 (pt) 2017-08-22
CA2697537A1 (en) 2009-03-12
JP2010538062A (ja) 2010-12-09
EP2197453A4 (en) 2010-10-20
CA2697496A1 (en) 2009-03-12
CN101835475A (zh) 2010-09-15
US20120121702A1 (en) 2012-05-17
KR20100054842A (ko) 2010-05-25
KR20100063088A (ko) 2010-06-10
ZA201001705B (en) 2010-12-29
AU2008296903A1 (en) 2009-03-12
EP2197453A1 (en) 2010-06-23
US8124123B2 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
CR20140340A (es) Formas farmacéuticas de dosificación oral resistente a interferencias que comprenden un analgésico opioide
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
SMT201500317B (it) Forma di dosaggio farmaceutica per la somministrazione orale di un inibitore della famiglia di bcl-2
BRPI0906467A2 (pt) forma de dose farmacêutica
CR11709A (es) Preparacion solida de desintegracion oral
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
DK2077729T3 (da) Orale probiotiske doseringsformer
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CL2012000626A1 (es) Composición farmacéutica oral de liberación sostenida, que comprende dentro de una forma de dosificación única, (i) una matriz hidrofílica, (ii) una cantidad terapéuticamente eficaz de un compuesto no opioide que contiene amina, (iii) una sal de un fármaco aine, y (iv) opcionalmente un surfactante aniónico.
GT200900096A (es) Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
BR112013009153A2 (pt) formulação de ligante de fosfato para dosagem única.
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI0719880A2 (pt) Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma.
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
BRPI0913235A2 (pt) forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
BRPI0922806A2 (pt) formas de dosagem oral de bendamustina
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata

Legal Events

Date Code Title Description
FA Abandonment or withdrawal